Hydroxychloroquine with or without Azithromycin in Covid-19 REPLY

被引：0
|
作者：
Cavalcanti, Alexandre B. [1 ]
Berwanger, Otavio [2 ]
Zampieri, Fernando G. [1 ]
机构：
[1] HCor Res Inst, Sao Paulo, Brazil
[2] Hosp Israelita Albert Einstein, Sao Paulo, Brazil
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2021年 / 384卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：191 / 191
页数：1
相关论文
共 50 条
  • [21] Lessons learnt from hydroxychloroquine/azithromycin in treatment of COVID-19
    Xu, Jiuyang
    Cao, Bin
    EUROPEAN RESPIRATORY JOURNAL, 2022, 59 (01)
  • [22] Hydroxychloroquine with azithromycin in patients hospitalized for mild and moderate COVID-19
    Lamback, Elisa Baranski
    de Oliveira, Monica Amorim
    Haddad, Andrea Ferreira
    Marcondes Vieira, Andre Filipe
    Ferreira Neto, Armando Leao
    Maia, Taciana da Silva
    Chrisman, Juliana de Rezende
    de Mello Spineti, Pedro Pimenta
    de Mattos, Marco Antonio
    Costa, Eduardo
    BRAZILIAN JOURNAL OF INFECTIOUS DISEASES, 2021, 25 (02):
  • [23] Investigation of QT Prolongation with Hydroxychloroquine and Azithromycin for the Treatment of COVID-19
    Seyhan, Avni Uygar
    Doganay, Fatih
    Yilmaz, Erdal
    Topal, Nurdan Papila
    Ak, Rohat
    JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN, 2020, 30 (10): : S153 - S157
  • [24] HYDROXYCHLOROQUINE AND AZITHROMYCIN COMBINATION COULD BE LETHAL TO COVID-19 PATIENTS
    Mohammad, Firdous Sayeed
    Karmakar, Varnita
    Irfan, Zainab
    FARMACIA, 2020, 68 (03) : 384 - 389
  • [25] COVID-19 AND QTC: IS HYDROXYCHLOROQUINE WORTH THE RISK? A REVIEW OF QT PROLONGATION IN HOSPITALISED COVID-19 PATIENTS TREATED WITH HYDROXYCHLOROQUINE AND AZITHROMYCIN
    Pollock, A.
    Kumar, R.
    Devitt, P.
    Kent, B.
    Daly, C.
    HEART, 2020, 106 : A1 - A1
  • [26] Hydroxychloroquine in Hospitalized Patients with Covid-19 Reply
    Horby, Peter
    White, Nicholas J.
    Landray, Martin J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (09): : 882 - 882
  • [27] Hydroxychloroquine as Postexposure Prophylaxis for Covid-19 Reply
    Okafor, Elizabeth C.
    Pastick, Katelyn A.
    Rajasingham, Radha
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (11): : 1089 - 1089
  • [28] Thrombotic microangiopathy: COVID-19 or hydroxychloroquine? Reply
    Wanchoo, Rimda
    Barilla-LaBarca, Maria Louise
    Jhaveri, Kenar D.
    KIDNEY INTERNATIONAL, 2020, 98 (06) : 1620 - 1620
  • [29] Reply to Gautret et al: hydroxychloroquine sulfate and azithromycin for COVID-19: what is the evidence and what are the risks?
    Machiels, Julian D.
    Bleeker-Rovers, Chantal P.
    ter Heine, Rob
    Rahamat-Langendoen, Janette
    de Mast, Quirijn
    ten Oever, Jaap
    Bousema, Teun
    van Crevel, Reinout
    Wertheim, Heiman F. L.
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2020, 56 (01)
  • [30] Re: 'Effect of hydroxychloroquine with or without azithromycin on the mortality of COVID-19 patients' by Fiolet et al.
    Lacout, Alexis
    Marcy, Pierre Yves
    Perronne, Christian
    CLINICAL MICROBIOLOGY AND INFECTION, 2021, 27 (01) : 134 - 135
12345